Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

NCT06359002 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed / Refractory AML
Relapsed / Refractory MDS

Interventions

DRUG: BYON4413

Sponsor

Byondis B.V.